Targeting the MEK signaling pathway in non-small cell lung cancer (NSCLC) patients with RAS aberrations.

doi:10.1177/1753465816632111

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Targeting the MEK signaling pathway in non-small cell lung cancer (NSCLC) patients with RAS aberrations.

Therapeutic advances in respiratory disease - 1 Jun 2016

Abdel-Rahman Omar

Abstract excerpt

With the advancement in understanding the biology of non-small cell lung cancer (NSCLC), therapies focused on novel molecular pathways have come to the forefront of NSCLC treatment. This review focuses on the preclinical and clinical aspects underlying the targeting of RAS aberrations in NSCLC with special focus on MEK inhibitors which work by inhibiting the principal downstream mediator of RAS aberrations with a...

Topics

Animals
Antineoplastic Agents
Carcinoma, Non-Small-Cell Lung
Drug Design
Humans
Lung Neoplasms
MAP Kinase Signaling System
Molecular Targeted Therapy
Mutation
Protein Kinase Inhibitors
Proto-Oncogene Proteins p21(ras)
Randomized Controlled Trials as Topic

Source

Open in PubMed Open full text

Identifiers

PMID: 26893312
DOI: 10.1177/1753465816632111
PMCID: PMC5933606

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics